The company has pioneered a breakthrough approach to the diagnosis and management of chronic diseases and cancer by utilizing proprietary technology to measure and categorize circulating nucleic acids in the blood. This technology identifies specific changes in disease and health status, allowing for the development of DNA-based assays. Chronix plans to collaborate with partners to transform the management of various cancers and other conditions. With its headquarters in San Jose, California, and research facilities in Germany, the company offers diagnostic test kits that enable healthcare professionals to easily detect cancer symptoms and monitor chronic diseases in humans and animals.